← Back to Screener
Citius Pharmaceuticals Inc. Common (CTXR)
Price$0.87
Favorite Metrics
Price vs S&P 500 (26W)-38.97%
Price vs S&P 500 (4W)1.83%
Market Capitalization$19.56M
All Metrics
Book Value / Share (Quarterly)$3.57
P/TBV (Annual)3.37x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.01
Price vs S&P 500 (YTD)6.33%
EPS (TTM)$-2.92
10-Day Avg Trading Volume0.29M
EPS Excl Extra (TTM)$-2.92
EPS (Annual)$-3.38
ROI (Annual)-54.61%
Cash / Share (Quarterly)$0.35
ROA (Last FY)-28.59%
EBITD / Share (TTM)$-2.52
ROE (5Y Avg)-39.45%
Cash Flow / Share (Annual)$-1.79
P/B Ratio0.24x
P/B Ratio (Quarterly)0.20x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-244.30x
ROA (TTM)-27.58%
EPS Incl Extra (Annual)$-3.38
Current Ratio (Annual)0.62x
Quick Ratio (Quarterly)0.31x
3-Month Avg Trading Volume0.75M
52-Week Price Return-13.22%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.73
52-Week High$2.48
EPS Excl Extra (Annual)$-3.38
Tangible BV CAGR (5Y)29.89%
26-Week Price Return-30.22%
Quick Ratio (Annual)0.09x
13-Week Price Return-0.54%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)0.99x
Enterprise Value$12.84
Book Value / Share Growth (5Y)43.89%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.24
3-Month Return Std Dev109.78%
Net Income / Employee (TTM)$-2
ROE (Last FY)-55.42%
Net Interest Coverage (Annual)-86.29x
EPS Basic Excl Extra (Annual)$-3.38
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-2.92
ROI (TTM)-51.97%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.95
Forward P/E0.53x
Price vs S&P 500 (52W)-48.31%
Year-to-Date Return10.46%
5-Day Price Return5.31%
EPS Normalized (Annual)$-3.38
ROA (5Y Avg)-27.85%
Month-to-Date Return-4.63%
Cash Flow / Share (TTM)$-0.21
EBITD / Share (Annual)$-3.48
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-39.29%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.92
P/TBV (Quarterly)3.64x
P/B Ratio (Annual)0.33x
Book Value / Share (Annual)$3.74
Price vs S&P 500 (13W)-3.41%
Beta1.19x
Revenue / Share (TTM)$0.18
ROE (TTM)-52.54%
52-Week Low$0.63
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CTXRCitius Pharmaceuticals Inc. Common | — | — | — | — | $0.87 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Citius Pharmaceuticals develops first-in-class targeted oncology therapies, with LYMPHIR—an engineered IL-2 diphtheria toxin fusion protein—as its flagship product candidate. The company addresses unmet medical needs in oncology and adjunct cancer care with a lower development risk profile than typical new chemical entities.